PAIN
Volume 150, Issue 3 , Pages 420-427 , September 2010

The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy

  • Ralf Baron

      Affiliations

    • Division of Neurological Pain Research and Therapy, Department of Neurology, Christian-Albrechts University, Kiel, Germany
    • Corresponding Author InformationCorresponding author. Address: Division of Neurological Pain Research and Therapy, Department of Neurology, Christian-Albrechts University, Schittenhelmstrasse 10, 24105 Kiel, Germany. Tel.: +49 (0) 431 597 8504; fax: +49 (0) 431 597 8530.
    • ,
  • Rainer Freynhagen

      Affiliations

    • Department of Anaesthesiology, Critical Care Medicine, Pain Therapy & Palliative Care, Benedictus Krankenhaus Tutzing, Germany
    • ,
  • Thomas R. Tölle

      Affiliations

    • Department of Neurology, Technische Universität München, Germany
    • ,
  • Christian Cloutier

      Affiliations

    • Clinique Multidisciplinaire de la douleur Centre Hospitalier, Université de Sherbrooke, Sherbrooke, Québec, Canada
    • ,
  • Teresa Leon

      Affiliations

    • Pfizer Global Research and Development, New York, NY, USA
    • ,
  • T. Kevin Murphy

      Affiliations

    • Pfizer Global Research and Development, New York, NY, USA
    • ,
  • Kem Phillips

      Affiliations

    • Pfizer Global Research and Development, New York, NY, USA
    • ,
  • on behalf of the A0081007 Investigators

Received 17 September 2009 ,Revised 28 February 2010 ,Accepted 12 April 2010.

References 

  1. Airaksinen O, Brox JI, Cedraschi C, Hildebrandt J, Klaber-Moffett J, Kovacs F, et al. COST B13 working group on guidelines for chronic low back pain. Chapter 4. European guidelines for the management of chronic nonspecific low back pain. Eur Spine J. 2006;15:S192–S300
  2. Arnold LM, Crofford LJ, Martin SA, Young JP, Sharma U. The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Med. 2007;8:633–638
  3. Baron R, Binder A. How neuropathic is sciatica? The mixed pain concept. Orthopade. 2004;33:568–575
  4. Bauer CS, Nieto-Rostro M, Rahman W, Tran-Van-Minh A, Ferron L, Douglas L, et al. The increased trafficking of the calcium channel subunit α2δ-1 to presynaptic terminals in neuropathic pain is inhibited by the α2δ ligand pregabalin. J Neurosci. 2009;29:4076–4088
  5. Blommel ML, Blommel AL. Pregabalin: an antiepileptic agent useful for neuropathic pain. Am J Health Syst Pharm. 2007;64:1475–1482
  6. Chou R, Huffman LH. American Pain Society, American College of Physicians. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med. 2007;147:505–514
  7. Chou R, Qaseem A, Snow V, Casey D, Cross JT, Shekelle P, et al. Clinical Efficacy Assessment Subcommittee of the American College of Physicians, American College of Physicians, American Pain Society Low Back Pain Guidelines Panel. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007;147:478–491
  8. Crofford LJ, Mease PJ, Simpson SL, Young JP, Martin SA, Haig GM, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136:419–431
  9. Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237–251
  10. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003;23:240–249
  11. Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain. Curr Pain Headache Rep. 2009;13:185–190
  12. Freynhagen R, Bennett MI. Diagnosis and management of neuropathic pain. BMJ. 2009;339:b3002
  13. Hayashida K, Obata H, Nakajima K, Eisenach JC. Gabapentin acts within the locus coeruleus to alleviate neuropathic pain. Anesthesiology. 2008;109:1077–1084
  14. Hendrich J, Van Minh AT, Heblich F, Nieto-Rostro M, Watschinger K, Striessnig J, et al. Pharmacological disruption of calcium channel trafficking by the α2δ ligand gabapentin. Proc Natl Acad Sci USA. 2008;105:3628–3633
  15. Khoromi S, Cui L, Nackers L, Max MB. Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain. 2007;130:66–75
  16. Khoromi S, Patsalides A, Parada S, Salehi V, Meegan JM, Max MB. Topiramate in chronic lumbar radicular pain. J Pain. 2005;6:829–836
  17. Luo ZD, Calcutt NA, Higuera ES, Valder CR, Song YH, Svensson CI, et al. Injury type-specific calcium channel α2δ-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther. 2002;303:1199–1205
  18. Luo ZD, Chaplan SR, Higuera ES, Sorkin LS, Stauderman KA, Williams ME, et al. Upregulation of dorsal root ganglion α2δ calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci. 2001;21:1868–1875
  19. Maizels M, McCarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. Am Fam Physician. 2005;71:483–490
  20. McCleane G. Does gabapentin have an analgesic effect on background, movement and referred pain? A randomised, double-blind, placebo controlled study. Pain Clinic. 2001;13:103–107
  21. McQuay HJ, Derry S, Moore RA, Poulain P, Legout V. Enriched enrolment with randomised withdrawal (EERW): time for a new look at clinical trial design in chronic pain. Pain. 2008;135:217–220
  22. McQuay HJ, Moore RA. Placebo. Postgrad Med J. 2005;81:155–160
  23. Pavelka K, Trč T, Karpaš K, Vítek P, Sedláčková M, Vlasáková V, et al. The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of a three-month treatment period. Arthritis Rheum. 2007;56:4055–4064
  24. Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I, et al. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology (Oxford). 2002;41:1346–1356
  25. Russell IJ, Crofford LJ, Leon T, Cappelleri JC, Bushmakin AG, Whalen E, et al. The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome. Sleep Med. 2009;10:604–610
  26. Sabatowski R, Galvez R, Cherry DA, Jacquot F, Vincent E, Maisonobe P, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004;109:26–35
  27. Schmidt CO, Schweikert B, Wenig CM, Schmidt U, Gockel U, Freynhagen R, et al. Modelling the prevalence and cost of back pain with neuropathic components in the general population. Eur J Pain. 2009;13:1030–1035
  28. Stein DJ, Baldwin DS, Baldinetti F, Mandel F. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol. 2008;18:422–430
  29. Tarulli AW, Raynor EM. Lumbosacral radiculopathy. Neurol Clin. 2007;25:387–405
  30. Tölle TR, Baron R, Freynhagen R, Leon T, Murphy TK, Phillips K. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with lumbosacral radiculopathy. Presented at: 12th World Congress of the European Federation of Neurological Societies; August 23–26, 2008; Madrid, Spain.
  31. Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. JAMA. 1994;271:1609–1614
  32. Yildirim K, Şişecioğlu M, Karatay S, Erdal A, Levent A, Uğur M, et al. The effectiveness of gabapentin in patients with chronic radiculopathy. Pain Clinic. 2003;15:213–218
  33. Zareba G. Pregabalin: a new agent for the treatment of neuropathic pain. Drugs Today (Barc). 2005;41:509–516

PII: S0304-3959(10)00219-8

doi: 10.1016/j.pain.2010.04.013

PAIN
Volume 150, Issue 3 , Pages 420-427 , September 2010

Article Tools

* Image Usage & Resolution